Kirpal Kooner The opportunity The investment thesis in CAPREIT (TSX:CAR.UN:CA) concerns the Canadian housing sector and its current affordability crisis. A specific mix of demographic, regulatory, and economic conditions has aligned to create a favorable environment for residential rental properties and apartment REITs. The demographic tailwind There is a saying in Canada that it takes five minutes for a family to arrive in Canada, and seven years for the country to build them a home. According to Stati ...

Two-storey residential building in Ottawa, Canada Iryna Tolmachova/iStock Editorial via Getty Images Note: All amounts discussed are in Canadian Dollars. Securities discussed trade primarily on Canadian exchanges. Canadian options are not accessible by US investors. On our last venture out into analyzing Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA), we upgraded the REIT to a Buy and after staying on the sidelines for about 18 months. Right or wrong, we prefer to make calls ba ...

PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, August 5th, 2024, and to host a conference call for institutional investors to discuss these results on Tuesday, August 6th, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to the ...

PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, August 5th, 2024, and to host a conference call for institutional investors to discuss these results on Tuesday, August 6th, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to th ...

Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. ...

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the California Institute for Regenerative Medicines (“CIRM”) has awarded an $8 million grant to Senti Bio. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen re ...

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration ...

Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; ...

This patient is expected to be the final patient in the second dosage cohort of the trialSAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the seco ...

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune diseaseKYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseasesEMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from auto ...